
ETHICAL & RATIONAL MANAGEMENT OF VERTIGO

Dr. Anirban Biswas Neurotologist Vertigo & Deafness Clinic Kolkata, India

Drugs & other Modalities

ETHICAL & RATIONAL MANAGEMENT OF VERTIGO



Objectives of management of vertigo

- Provide symptomatic relief taking care of the inherent ill-effects of antivertigo drugs
- Diagnose the cause of the vertigo and <u>treat the cause of the vertigo</u> rather than merely suppress & camouflage the symptom of vertigo
- Treat the co-morbidities esp the psychological and cognitive impact of the balance disorder
- Restore the deranged balance function possible only by physical therapy in different formats

Vestibular physiotherapy

Physical therapy to restore normal balance function after it has been deranged by disease. Acts by:-

 enhancing the vestibular compensatory mechanism
improving the general balance function and sharpening the balancing skills of the subject
enhancing the functionality of a damaged part of the vestibular labyrinth or of a deranged mechanism in the vestibular system

What is new in today's scenario ??

- Our understanding of vestibular physiology has undergone immense refinement; the morbidity of the balance disorder patient is now much better understood
- Any lesion in the vestibular system can be very precisely diagnosed with pin-point accuracy; specific therapy is now available for most if not all balance disorders
- The pharmacology of the anti-vertigo drugs and their mechanism of action in the balance disorder patient is now much better known; some drugs are now proved to be a complete hoax or just a placebo, some are found to have serious adverse effects and all jeopardise the vest compensatory mechanism
- Very specific treatment is available for most causes of balance disorders today; management now involves treating the co-morbidities also
- Vestibular physiotherapy targeted to specific organs in the vestibular system is now a reality; hence relevance of anti-vertigo drugs is much lesser now

Anirban Biswas, Neurotologist

Balance disorder patients are not just



Vertigo




Imbalance


-- they have a lot of other problems

Or



Irrational behavior





Forgetfulness

Poor concentration Anirban Biswas, Neurotologist

Balance disorder patients have COGNITIVE deficits and show poor cognitive skills in the domains of:-



Arithmetic and reading

Memory

Concentration

Anirban Biswas, Neurotologist They also have psychological and emotional disorders

VERTIGO or IMBALANCE are just one of their many problems A HOLISTIC MANAGEMENT is NEEDED




Some undisputed basics relevant to therapy

- Vertigo / imbalance is just a *symptom* or manifestation of an underlying disorder; the causative pathology needs to be known for treatment
- Objective of management is to correct the cause, (not merely suppress the symptom) and to promote balance restoration by stimulating the deranged balance system and by enhancing vestibular compensation
- Vestibular compensation is a natural process but can be expedited by physio therapy and inhibited by CNS depressants and the anti-vertigo drugs
- Central disorders and bilateral vestibulopathy usually present with imbalance; suppressing vestibular sensitivity by vestibular sedatives will aggravate the imbalance as CNS gets deprived of normal vestibular input

Some undisputed basics relevant to therapy

- Vertigo / imbalance and psychogenic as well as cognitive disorders are co-morbid conditions that need effective management
- Neurotropic agents / antioxidants / cognition enhancing drugs have a *positive* role in the management of balance disorders
- Prolonged use of anti-vertigo drugs is hazardous and detrimental to the balance system; current recommendation for duration of therapy with anti-vertigo drugs is <u>3-5 days</u> maximum 7 days,



Sensory conflicts that increase vertiginous symptom enhances compensation

Anirban Biswas, Neurotologist

This is what the world believes today...

Anirban Biswas, Neurotologist

Sman J. Hendman Richard A. Chendarini

Vestibular Rehabilitation

burrentik kommense

valacyclovir offer no therapeutic advantage.³⁶ There is a consensus that drugs exerting a "sedative effect" on the vestibular system should be used for only the first 24 hours.¹⁰ Some drugs commonly used for treatment of vertigo, nausea,

Page 253 Chapter 14

 Baloh RW, Kerber KA. Clinical Neurophysiology of the Vestibular System. Fourth ed. New York: Oxford University Press, 2011.

R

More than 95% patients of vertigo/ imbalance are due to-

- BPPV
- Vestibular neuritis
- Migraine related vertigo
- Psychogenic vertigo e.g., PPV / PPPD / Spont MdDS
- Labyrinthitis
- Meniere's disease
- Vestibular siezures
- Sensory ataxia /posterior column lesions
- Ototoxicity
- Central vertigo due to oculomotor or other CNS diseases like extrapyramidal disorders




More than 95% patients of vertigo/ imbalance are due to-

- **BPPV......26%**
- Vestibular neuritis......4%
- Specific therapies exist for all of them

ne require long continued non-specific with anti-vertigo drugs eran Central vertigo due to oculomotor or other CNS diseases like extrapyramidal/ cerebellar disorders/ NPH5%

Anirban Biswas, Neurotologist

Specific therapy for BPPV



Specific therapy for VESTIBULAR NEURITIS

VESTIBULAR NEURITIS

Specific therapy for VERTIGINOUS MIGRAINE

MIGRAINE RELATED VERTIGO

Specific therapy for PHOBIC POSTURAL VERTIGO

PHOBIC POSTURAL VERTIGO

Specific therapy for LABYRINTHITIS



Specific therapy for MENIERE'S DISEASE



RESEARCH

Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial)

BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.h6816 (Published 21 January 2016)

Discussion

Principal findings

For patients with Meniere's disease, unpredictable vertigo attacks are the most unpleasant symptom, leading to not just physical but also psychological strain. Clinical experience and several studies have supported a potential beneficial effect of prophylactic drug treatment with betahistine on the attacks of vertigo as well as on vestibular and, to a lesser degree, audiological symptoms. However, according to a Cochrane review of betahistine for Meniere's disease or Meniere's syndrome, there is insufficient evidence to say whether betahistine has any effect.

RESEARCH

Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial)

BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.h6816 (Published 21 January 2016)

The key findings of the BEMED trial are as follows:

• A significant decline of attack rates in each treatment arm was observed over the nine month treatment period

• The effects of two different doses of betahistine could not be distinguished from a patient reported effect caused by placebo intervention in terms of the incidence of attacks as well as vestibular and audiological function and quality of life. <u>Therefore, the results do not give clear evidence that</u> <u>patients have a relevant clinical reduction in the number of attacks after nine months of treatment</u> <u>with betahistine at a daily dose of 48 mg or 144 mg, compared with a placebo (sham) intervention</u>

• There were no safety concerns, and betahistine was well tolerated even in the high dose group of 144 mg betahistine per day.

Specific therapy for VESTIBULAR SEIZURES

VESTIBULAR SEIZURES

Specific therapy for VESTIBULAR PAROXYSMIA

VESTIBULAR PAROXYSMIA

Specific therapy for SENSORY ATAXIA

SENSORY ATAXIA / Posterior column lesions

Specific therapy for BILATERAL VESTIBULOPATHY



Specific therapy for CENTRAL VERTIGO



Managing the main COMORBIDITIES

VERTIGO – are there definite COGNITIVE & PSYCHIC aspects that need effective management ? Is mental stress / anxiety an issue in balance disorders?

If so what is the logic and why and how to manage them??

COGNITION & maintenance of balance

Maintenance of balance involves:-

-understanding (acquiring knowledge) of ongoing reality through the visual, proprioceptive and vestibular senses *-perception*,

-establishing coherence between these different sensory inputs and by comparing with previously stored experiences *— integration & memory recall*

-integrating the inputs in the brain to comprehend the reality about the stability of the ground & the surroundings

-executing a motor action based on the integrated inputs to maintain stability and prevent a fall *—execution of a programed response*

This is a real cognitive process



COGNITION & maintenance of balance

(contd)

Maintenance of balance involves:-

- Adaptation to the ongoing reality and storing in the brain (memorisation of) experiences learnt pertaining to the maintenance of balance
- Prediction of the expected response by comparing with the previously stored experiences
- Innovating (usually by intuition) newer strategies to maintain balance when similar experiences are not stored in the brain or when contradictory inputs are received in the brain

All these too are real cognitive processes

COGNITION & maintenance of balance

- Maintenance of balance as well as the process of vestibular compensation is all about:-
- -learning and re-learning (*acquiring knowledge*) how to make best use of the available inputs
- -evolve strategies (*reasoning using past experiences stored in memory*) about how to stay erect and prevent a fall
- -achieve a goal by contracting some body muscles (*executing an action*) both in health as well as in disease

all of which together is a COGNITIVE process

COGNITION & Vestibular Compensation

Compensation and Adaptation involves:-

 Intelligently utilising the available inputs to maintain balance after a vestibular damage has taken place

 Evolving newer strategies to maintain balance as requisite inputs are not available after a vestibular damage

Both these are COGNITIVE processes

PSYCHIC impact of BALANCE DISORDERS

- 64% of vertigo patients had psychiatric symptoms - Kenna, Hallam, Hinchcliff Otolaryngol 1991 - 45% of vertigo patients had panic symptoms - Cleark, Hirsch, Smith Am J. Psychiatry 1994

Studies show :-

22 to 67% incidence of anxiety & agoraphobia in dizziness patients


39 to 88% incidence of vestibular abnormality in panic patients.



The vestibular –pshychiatric interrelationship :-

- 1.Psychiatric patient (esp.schizophrenics) more susceptible to motion sickness
- 2. Schizophenic patients have higher incidence of abnormal findings on vestibular function test
- 3. Dizziness/instability is one of the common features of panic attacks
- 4. Incidence of definite psychiatric disorder very high in patients with proved vestibular dysfunction.

The vestibular –psychiatric interrelationship (Contd.) :-



A vicious cycle.....

Dizziness

(Severe vertigo persistent dizziness imbalance autonomic symptoms)

Negative beliefs (serious incurable disease, no treatment possible)

Psychological disorders (anxiety, panic avoidance, somatisation, depression)

Restrict movement (poor vestibular compensation)

Psychological disorders commonly encountered in dizziness patients :-

- Anxiety
- Helplessness
- Agoraphobia
- Somatisation (hypochondria)
- **Depression**
- **Conversion disorders**



MANAGEMENT


1. Reassurance : explanation about

- benign nature of pathology
- dizziness & psychopathology interrelationship
- high prevalence of disorder
- 2. Psychotherapy
 - cognitive behavioral therapy
 - psychotherapy
- 3. Pharmacotherapy
 - benzodiazepins
 - antidepressants





A new medication claimed to be non-CNS depressant to reduce stress and manage sleeplessness



Mental Relaxation



• LACTIUM is an bioactive decapeptide having relaxing properties, derived from milk



• L-THEANINE is naturally occurring amino acid mainly found in Green tea leaves



Claimed to be World's only proven anti-stress therapy





- Effective and safe formula for managing stress & disturbed sleep
- Clinically proven efficacy and safety in numerous trials
- Clinically proven to reduce physical, physiological and psychological symptoms of stress (e.g., digestive, cardiovascular, intellectual, social & emotional symptoms)
 - Stimulates brain alpha waves and induces relaxation within 40 mins





- Manufacturers produced literature showing that the drug :-
- Reduces Cortisol level Major biomarker of stress

Improves sleep quality & restores natural sleep

 Completely safe and no scary adverse effects (does not cause sedation, habituation, addiction, dependence, memory impairment etc.)







The antivertigo drugs- an analytical if not a cynical review



Finding out the least harmful one !!

- **1. Dimenhydrinate**
- 2. Diazepam
- 3. Proclorperazine
- 4. Promethazine
- 5. Cinnarizine
- 6. Betahistine
- 7. Meclizine
- 8. Ginkgo biloba



PROCHLORPERAZINE

- belongs to the phenothiazine group of antipsychotics known to induce extrapyramidal disorders like PARKINSONISM, chorea dystonia ects that with oculogyric crisis, spasticity, opisthotonus, tortic <u>m, etc.</u>
- pharmacologically recommended
- antidopaminer : any side office of the side of the sid
- clinicians need to be aware of vegetative accompany acute vertigo like nausea, vomiting are reatly relieved.

ADVERSE EFFECTS OF PROCHLORPERAZINE

 Extrapyramidal effects like acute dystonic reactions, oculogyric crises, pseudo parkinsonism and akathisia are the major drawbacks
more common in children and adolescents.

- can also cause a life threatening condition called neuroleptic malignant syndrome
- Sublingual preparation sometimes causes local erosive cheilitis of lips and tongue (patient can swallow the tablet in such situation)
- Hypotension, esp orthostatic hypotension not uncommon
- anticholinergic effects are often very distressing for the patient

CINNARIZINE

• Provides good symptomatic relief

Increases blood supply to the brain and inner ear

• Not known to have any teratogenic effect

• But has too many side-effects -hence best abhorred







Adverse effects of Cinnarizine in long term use in high dosage

Xerostomia

CINNARIZINE 25 to 75mg thrice daily

- labyrinthine sedative effect ; hence provides reasonably good symptomatic relief.
- anti-vasoconstrictive effect
- reduces slugging phenomenon of blood in narrow blood vessels
- stabilises vascular endothelium
- Anticholinergic drug hence induces CNS depression
- Side effects like pedal oedema, drowsiness, extrapyramidal symptoms like Parkinsonism/ tremor anticholinergic effects





BETAHISTINE 24-1440mg/day

- Provides symptomatic relief by ? sedating ? stimulating the vest labyrinth
- Increases blood flow to brain and inner ear
- Does not depress the CNS
- Only non-sedative anti-vertigo drug without any anti-cholinergic and anti-dopaminergic effects

but

- Mechanism of action very confusing and unclear
- Controversies in dosage (24 900mg/day)
- Proved to be a *placebo* only without any medicinal effect

What is it actually?

H1 and H2 receptors have postsynaptic excitatory action on the vestibular system.

- H3 receptor presynaptic autoreceptor (reduces histamine)
- H4 receptors outside CNS have inhibitory vestibular action.

This drug has both excitatory and inhibitory actions, hence, delusion lies in its very existence.

It used to be advocated as a vestibular suppressant but now clamed to be a stimulant of the vestibular system

What the manufacturers /promoters have understood about mechanism of action of BETAHISTINE

FOUDDUCT MOREOGRAPHY * 43-367. as more interaction account of strands and was all and all the the ball sectors of the Familaday Docate MERICO tion of the second second M. Lapana Tank average \$1. W Revealer, Column 100 100 This of Distance Caroliner 人名法法法 Transfer ins days Aug. 1, 2020 Want share County Nor "Black Inst.Pyteries Managers 10011-011 lay in Resource Address in State york interesting you wind

ACTION AND CLINICAL PHARMACOLOGY

tär develigende allers her som äll inges to der versioniske medier. Behelter ige

the same of the second s

Mechanism of Action

the side of the set of

The mechanism of action of betalusting dihydrochloride is only profix understand. There are several plansible hypotheses that are supported by animal studies and human data.

Betahisting dihydrochloride affects the histaninergic system: Detah sing dihydrochloride acts both is a portial histamine II₁ receptor agonist and histamine II₂ receptor an agonist in neuronal. tissue, and has negligible Hy receptor activity. Hetainstine dihydrochlaride increases histornine. function and release by blocking presynaptic Hurceeprors and inducing Hurceepror. kom agriatore -

Retabisting diliveragin once may increase blood flow to the coefficient region: Pharmacological testing in all mais has shown that the blood enculation in the strine vascularis of the uncertest. improves, proceedly by means of a relevation of the processibility sphereters of the microcirculation of the inner ear,

> BAL Frank Revenant. Life Parkare, which I, Not the Chart IV, 1960

Pen In'll

ا () ا مورا

ing A / Life Manager

Betahistine is a vestibular SUPPRESANT

And A second second Property in the second s


142

Betabistine treatment in managing vertige and improving vestibular compensation: Clarification

Michel Linder" 1944 New Collision of Architecture Topology The Arcenter M. Lacour / Vertigo, vestibular compensation, and betahistine.

M. Lacour / Vertigo, outsidedia compensation, and benchizing

CONTRACTOR OF A DESCRIPTION OF A DESCRIP



DILEMMA

- It was suggested that betahistine causes inhibition of activity in the vestibular nuclei (Timmerman 1994).
- Betahistine reduces vestibular input (Lacour 2013)
- But, vestibular sedatives cannot be prescribed for more than 3-5 days as per current consensus, so now touted as vestibular stimulant!
- Doesn't this leave us all the more deluded?

The chequered history of Betahistine

 Serc(brand name for betahistine)was approved by the US FDA about 50 years ago for roughly 5years, but later approval was withdrawn.

 Subsequently, four double blind studies have been done reporting reduction of vertigo attacks with betahistine (Frew and Menon, 1976: Wilmot and Menon; 1976; Meyer, 1985; Mira et al, 2003).


The chequered history of Betahistine

• A review suggested that it is presently still unclear if betahistine has any effect in Meniere's disease (James and Burton, 2001).

• Reviewed by the "Cochrane database", in 2009 which concluded insufficient evidence to prove its action.

• A recent study of hydrops also found that betahistine had no effect (Gurlov et al, 2012).

• Currently not approved by FDA for use in USA



So to summarize, evidence is weak for betahistine being an effective treatment of Meniere's. Our guess is that it is mildly effective, and fortunately it has very few adverse effects (see following).

Betahistine increases cerebral and inner ear blood flow

• The increased blood flow is due to its action both on H1 and H3 receptors

- The much hyped H1 agonistic action is pretty weak-this action was observed only at levels which were 100 fold higher than therapeutic.
- Moreover this action is negated by the antihistaminic group of drugs
- However due to its H3 antagonistic effect ?some increase in vestibulocochlear blood flow may be possible

BETAHISTINE and vest. comp

Betahistine has been shown to enhance vestibular compensation and facilitate recovery of balance function in a 1995 study by Tighilit et al



But this study was on cats and not a human study and dose used was 100 times the recommended therapeutic dose for humans

Placebo and betahistine have same results .

CHEN ACCERT

RESEARCH

Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial)

Christine Adnors^{1,2} Carolin Simone Hischer,¹ Lichth Wagner,¹ Robert Silirkov,^a Utrith Mansmann,¹ Michael Strupp^{1,1} On behalf of the BEMED study group

WHAT THIS STUDY ADDS

Long form prophyloctic meatment with beta histon dihyclochlonide (at daily doses) 2424 mg or 3×48 mg) does not change the time course of vertiga episodes related to Mercine's disease contrained with placebu

Placebo intervention as well as betablishing the amount showed the same reduction of attack rates over the study's nine month treatment period.

Reliable and valid instruments that measure subjective vertigo synctoms (in particular, vertigo attacks caused by Meniere's disease) are lacking; derivation of definite approbable attacks caused by Meniere's disease, on the basis of raw patient recordings in vertigo diaries, is methodologically challenging and requires prespecified rules.

History AMARANA, EAGRIA Jane 1071 (Sportplettin

RESEARCH

Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial)

BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.h6816 (Published 21 January 2016)

Discussion

Principal findings

For patients with Meniere's disease, unpredictable vertigo attacks are the most unpleasant symptom, leading to not just physical but also psychological strain. Clinical experience and several studies have supported a potential beneficial effect of prophylactic drug treatment with betahistine on the attacks of vertigo as well as on vestibular and, to a lesser degree, audiological symptoms. However, according to a Cochrane review of betahistine for Meniere's disease or Meniere's syndrome, there is insufficient evidence to say whether betahistine has any effect.

RESEARCH

Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial)

BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.h6816 (Published 21 January 2016)

The key findings of the BEMED trial are as follows:

• A significant decline of attack rates in each treatment arm was observed over the nine month treatment period

• The effects of two different doses of betahistine could not be distinguished from a patient reported effect caused by placebo intervention in terms of the incidence of attacks as well as vestibular and audiological function and quality of life. <u>Therefore, the results do not give clear evidence that</u> <u>patients have a relevant clinical reduction in the number of attacks after nine months of treatment</u> <u>with betahistine at a daily dose of 48 mg or 144 mg, compared with a placebo (sham) intervention</u>

• There were no safety concerns, and betahistine was well tolerated even in the high dose group of 144 mg betahistine per day.

DIMENHYDRINATE

Conventional antihistaminic with high anti-cholinergic activity.

Mechanism of action: inhibits spread of hyperactive vestibular input via MLF to centers for vegetative regulation in medulla -e.g-centers for heart rate, respiration, vomiting, sweating etc.

Thus very effective in acute vertigo with pronounced vegetative symptoms

Absence of extrapyramidal features is the biggest advantage of this antiemetic.

Adverse effects of DIMENHYDRINATE in recommended therapeutic dosage



Highly sedative-impairs psychomotor skill. Concomitant use of alcohol or other CNS depressant should thus be discouraged.

Adverse effects of DIMENHYDRINATE in long term use




Better avoided in patients having enlarged prostate, glaucoma, emphysema, chronic bronchitis. – *applies to other anticholinergics too like cinnarizine meclizine*

Adverse effects of DIMENHYDRINATE in long term use

At very high doses it can affect color discrimination, night vision, visual reaction time, stereopsis

A new entrant in the anti-vertigo drug market




FIXED DRUG COMBINATION OF CINNARIZINE AND DIMENHYDRINATE

Cinnarizine + Dimenhydrinate - Summary of Literature review

- 1) first line drug for symptom control in VERTGO in different disorders
- 2) high Anti-vertiginous efficacy for the fixed combination in various vestibular disorder
- 3) more efficient in reducing vertigo and associated vegetative symptoms than the routinely prescribed Betahistine
- 4) as effective as Betahistine in Meniere's disease
- 5) no signs of a possible detrimental influence of the 4-week treatment with the fixed combination compared with Betahistine in terms of recovery of caloric responsiveness and abatement of rotation-induced nystagmus.
- 6) Does not impair alertness

The current consensus on management-

- Diagnose the cause of the balance disorder and treat the cause of the vertigo rather than camouflage the symptom of vertigo by eternal continuation of anti-vertigo drugs/ vestibular sedatives
- Treat holistically taking care of the co-morbidities like psychological and cognitive problems induced by the balance disorder



Take home message:-

- -Today the UNDERLYING PATHOLOGY AND SITE OF LESION CAN BE DIAGNOSED very accurately in most if not all patients of vertigo
- -RESTRICT use of symptom relieving anti-vertigo drugs to 3-5 days and only for acute vertigo; only use drugs that are efficacious and has a logical mech. of action
- -TREAT the underlying disorder causing the vertigo, rather than camouflage the symptom of vertigo
- -EXPEDITE vestibular compensation through organ targeted physical therapy as this is the only way to restore balance
- -TREAT the concomitant PSYCHOLOGICAL and COGNITIVE impairment for a complete recovery



